The Use of Metformin and Survival Causes in Patients with Type 2 Diabetes

• Main Authors: Je-Wei Tsai, 蔡哲維
• Other Authors: Shuo-Yan Chou
• Format: Others
• Language: en_US
• Published: 2015
• Online Access: http://ndltd.ncl.edu.tw/handle/48805745071331721431

碩士 === 國立臺灣科技大學 === 工業管理系 === 103 === Background and objective: Being as a global important health issues and top 10 most fatal cancers in Taiwan, diabetes associate with increased risk of certain cancers. At the forefront of diabetes Pharmacology found, it may be inhibited cancer cells, reduce the risk of getting cancer and mortality effect. This study explored the association of diabetes and cancer with diabetes drug(metformin) and investigated whether the positive effect for cancer by conducting the statistical approach. Methods: Study objects were identified from the NHIRD with diagnosis of cancer between 2000 and 2005 and tracked to 2009. In a cohort of 3,113 patients with cancer and aged over 40 years old, are divided into experimental and control groups. Logistic-Regression, Survival Analysis and Cox Proportional Hazard were used for comparison between groups. Results: Diabetes comorbidities patients the Top Five Cancers case are divided into treatment and non-treatment groups. According to the Cox proportional hazard model adjusted for age, sex and frequency of drug. It showed a decreased hazard ratio (HR) of 0.75(95% CI, 0.51-1.01) of lung cancer, 0.83(95% CI, 0.64-1.04) of liver cancer, 0.85(95% CI, 0.68-1.04) of breast cancer, 0.90(95% CI, 0.65-1.18) of oral cavity cancer, in patients with treatment, but it was not statistically significant. A significant effect was found between colorectum cancer (HR, 0.73(95% CI, 0.55-0.98)). Conclusions: This study provides a comprehensive analysis on impacts of diabetes drug with comorbidities in risk of cancers among diabetes patients. The risk may decrease further on patients in using metformin group.